Longevity tech startup NewLimit completes $435 million Series C funding at a valuation of $3.1 billion
Longevity technology startup NewLimit announced the completion of a $435 million Series C funding round, with a valuation of $3.1 billion. This round was led by Founders Fund, a fund under Peter Thiel, with continued participation from Abstract Ventures, Kleiner Perkins, NFDG, Eli Lilly Ventures, and Valor Equity Partners, while also bringing in new investors such as Thrive Capital, Greenoaks, and Quiet Capital.In 2021, Brian Armstrong, along with former GV partner and bioengineer Blake Byers, and stem cell biologist Jacob Kimmel, jointly invested $110 million to establish NewLimit in South San Francisco.